Preferences of Individuals in the United States With Personal Experience of Cancer for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 998
- 试验地点
- 1
- 主要终点
- Preferences for treatment attributes and trade-offs between attributes.
研究概览
简要总结
To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.
It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.
This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.
To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Individuals previously or currently diagnosed with any type of cancer.
- •Individuals with immediate family members previously or currently diagnosed with any type of cancer.
排除标准
- •Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).
结局指标
主要结局
Preferences for treatment attributes and trade-offs between attributes.
时间窗: Through study completion, an average of 4-8 weeks.
Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire. Preferences are measured on relative utility scale (arbitrary units, no min/max). Utility indicates preference e.g., higher values are more preferred (better).
次要结局
未报告次要终点
研究者
Robin Forrest
Principal Investigator
London School of Economics and Political Science